Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials
Paula Rı́o(Centre for Biomedical Network Research on Rare Diseases), Jordi Barquinero(Vall d'Hebron Institut de Recerca), Marina Cavazzana(Université Rennes 2), Philipp John-Neek(Medizinische Hochschule Hannover), Anne Galy(Centre National de la Recherche Scientifique), Juan A. Bueren(Centro de Investigación Biomédica en Red), Albert Català(Hospital Sant Joan de Déu Barcelona), Eva Heredero Gálvez(Hospital Municipal de Badalona), Manuel Ramı́rez(Hospital Infantil Universitario Niño Jesús), Laura García‐García(Universidad de Navarra), Elena Sebastián(Queen's University Belfast), Susana Navarro(Centre for Biomedical Network Research on Rare Diseases), Josune Zubicaray(University of Southern Denmark), Lise Larcher(Centre National de la Recherche Scientifique), María Fernández-García(Centre for Biomedical Network Research on Rare Diseases), Omaira Alberquilla(Cipher Gene (China)), Thierry Leblanc(Jet Propulsion Laboratory), Nagore García de Andoín(Biogipuzkoa Health Research Institute), Axel Schambach(Boston Children's Hospital), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), José C. Segovia(Unidades Centrales Científico-Técnicas), Antonella Lucía Bastone(Medizinische Hochschule Hannover), Julián Sevilla(University of Southern Denmark), Manfred Schmidt(Centre National de la Recherche Scientifique), Jean Soulier(Centre National de la Recherche Scientifique), Rebeca Sánchez‐Domínguez, Rosa María Pérez Yáñez(Instituto de Salud Carlos III), Sandra Rodríguez(Spanish National Cancer Research Centre), Ricardo López Almaraz(BioCruces Health research Institute), Jordi Surrallés(Universitat Autònoma de Barcelona), Jonathan D. Schwartz(Temple University), Massimo Bogliolo(Universitat Autònoma de Barcelona), Eileen Nicoletti(Sunesis (United States)), Wei Wang(First Affiliated Hospital of Guangzhou Medical University), Roser Pujol(Universitat Autònoma de Barcelona), Michael Rothe(American Society of Clinical Oncology), François Lefrère(Hôpital Necker-Enfants Malades), Begoña Díez(Centre for Biomedical Network Research on Rare Diseases), Gayatri R Rao(Sunesis (United States))
Cited by 27
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k